Corporate | 25 October 2004 08:44

MorphoSys to Present at Rodman & Renshaw Techvest Healthcare Conference

Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– MorphoSys to Present at Rodman & Renshaw Techvest Healthcare Conference MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) announced today that the company will be presenting at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference on Tuesday, October 26, 2004. The conference is being held at the Waldorf Astoria Hotel in New York City. Dave Lemus, Chief Financial Officer of MorphoSys, will present at 12:35 PM (ET) in the Starlight Roof North. MorphoSys’ presentation will be webcast live and will be available for replay through the MorphoSys website via the Internet at http://www.morphosys.com. About MorphoSys: MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company’s proprietary Human Combinatorial Antibody Library (HuCALâ) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Biogen Idec Inc. (Cambridge, Massachusetts/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (Wilmington, Delaware/USA), Centocor Inc. (Malvern, Pennsylvania/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Novartis AG (Basel, Switzerland), Novoplant GmbH (Gatersleben/Germany), Oridis Biomed GmbH (Graz/Austria), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA). For further information please visit the corporate website at: http://www.morphosys.com/ Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, “forward-looking statements” for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company’s proprietary rights and other factors described in the prospectus relating to the company’s recent public offering. For more information, please contact MorphoSys: Dr. Claudia Gutjahr-Löser, Director Corporate Communications, Tel. +49 (0)89 89927 122, gutjahr@morphosys.com / Mario Brkulj, PR Specialist, Tel. +49 (0)89 89927 454, brkulj@morphosys.com end of message, (c)DGAP 25.10.2004 ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: TecDAX Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 250844 Okt 04